for Patients Living with Serious Rare Conditions
VectivBio AG is a global biotechnology company committed to making a difference in the lives of patients
suffering from serious rare conditions.
We are assembling a best-in-disease pipeline in rare diseases, with a leading program aimed at patients living with Short Bowel Syndrome.
We are headquartered in Basel (Switzerland). We also have business operations in the New York area.
News & Media
Oct 15, 2020
VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases
VectivBio AG, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced it has closed a $110 million crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfer Initiative and Cowen Healthcare Investments.